3Rex J H, Rinald M G. Resistance of Candida species to fluconazole[J]. Antimicrob Agents Chemoter,1995;39(1):1.
4Espinal-ingroff A, Kerkering T M,Goldson P R, et al.Comparison study of broth macrodilution and microdilution antifungal susceptibility tests[J].J Clin Microbiol, 1992 ;30(12)3138.
5Galgiani J N,Reiser J, Brass C,et al. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods [ J]. Antimicrob Agents Chemother, 1987,31(9) : 1342.
6National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts[S].Approved standard. Document M27- A. N27- A.National Committee for clinicalLaboratory Standards, Wayne Pa 1997:24.
7Horsburgh C A, kirkpatrick C H. Long - term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients [J] .Am J Med,1983;74(1) :23.
8Akora M, Akalin H E, Uzum O, et al. Emergence of Candida krusei infections after therapy of oropharyneal candidiasis with fluconazole [J]. Eur J Clin Microbiol Infect Dis. 1991;10(3):598.
9Darouiche R O. Oropharyngeal and esophageal candidiasis in immunocompromisd patients: treatment issues[J]. Clin Infec Dis,1998,26(2) :259.
10Lewis R E, Klepser M E. The changing face of nosocomial candidemia: epdemiology,resistance and drug therapy [ J]. Am J Health Syst Pharm. 1999,56(6) :525.
